[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. 1985

K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro

5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day. Out of 13 evaluable cases 2PR, 2MR, 4NC and 5PD were observed, response rate was 15.4%. PR were obtained in one gastric cancer case and one breast cancer case. Side effects were observed in 6 cases out of 14 cases (42.9%) and major adverse reaction was gastro-intestinal toxicities such as anorexia, nausea-vomiting and diarrhea. Two leukocytopenia and one erythrocytopenia were observed. This study indicated that 5'-DFUR would be useful as a new anticancer agent.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005467 Floxuridine An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. FUdR,Fluorodeoxyuridine,5-FUdR,5-Fluorodeoxyuridine,5 Fluorodeoxyuridine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
May 1985, Gan no rinsho. Japan journal of cancer clinics,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
April 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
June 1983, Nihon Gan Chiryo Gakkai shi,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
June 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
October 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
April 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
October 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
March 1996, Oncology reports,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
April 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
K Irie, and K Yasutake, and Y Imamura, and Y Yoshimura, and M Yoshida, and T Nakamura, and I Suehiro
December 2005, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!